Drug: Imbruvica (Ibrutinib, AbbVie, Johnson & Johnson)
Status: The therapy is approved as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).
Significant Trial Data:
- Two hundred and sixty-nine treatment-naive patientswere randomized to receive either ibrutinib 420 mg orally, once daily until progression or unacceptable toxicity, or chlorambucil(Lukeran, GlaxoSmithKline)on days 1 and 15 of each 28-day cycle for up to 12 cycles.
- Ibrutinib reduced the risk